Literature DB >> 27471776

Activation of Nicotinic Acetylcholine Receptors Decreases Apoptosis in Human and Female Murine Pancreatic Islets.

Philippe Klee1, Domenico Bosco1, Audrey Guérardel1, Emmanuel Somm1, Audrey Toulotte1, Pierre Maechler1, Valérie M Schwitzgebel1.   

Abstract

Type 1 diabetes (T1DM) results from destruction of most insulin-secreting pancreatic β-cells. The persistence of β-cells decades after the onset of the disease indicates that the resistance of individual cells to the autoimmune insult is heterogeneous and might depend on the metabolic status of a cell at a given moment. The aim of this study is to investigate whether activation of nicotinic acetylcholine receptors (nACh-Rs) could increase β-cell resistance against the adverse environment prevailing at the onset of T1DM. Here, we show that nACh-R activation by nicotine and choline, 2 agonists of the receptor, decreases murine and human β-cell apoptosis induced by proinflammatory cytokines known to be present in the islet environment at the onset of T1DM. The protective mechanism activated by nicotine and choline involves attenuation of mitochondrial outer membrane permeabilization via modulation of endoplasmic reticulum stress, of the activity of B-cell lymphoma 2 family proteins and cytoplasmic calcium levels. Local inflammation and endoplasmic reticulum stress being key determinants of β-cell death in T1DM, we conclude that pharmacological activation of nACh-R could represent a valuable therapeutic option in the modulation of β-cell death in T1DM.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27471776     DOI: 10.1210/en.2015-2057

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  4 in total

1.  β-Cell mass restoration by α7 nicotinic acetylcholine receptor activation.

Authors:  Dhananjay Gupta; Adam A Lacayo; Shane M Greene; John L Leahy; Thomas L Jetton
Journal:  J Biol Chem       Date:  2018-11-05       Impact factor: 5.157

Review 2.  Potential Therapeutic Targeting Neurotransmitter Receptors in Diabetes.

Authors:  Xiaohui Pan; Shibing Tao; Nanwei Tong
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-20       Impact factor: 6.055

Review 3.  Therapeutic potential of α7 nicotinic acetylcholine receptor agonists to combat obesity, diabetes, and inflammation.

Authors:  Han Xie; Natesh Yepuri; Qinghe Meng; Ravi Dhawan; Colin A Leech; Oleg G Chepurny; George G Holz; Robert N Cooney
Journal:  Rev Endocr Metab Disord       Date:  2020-08-26       Impact factor: 6.514

4.  Nicotinic acetylcholine receptor signaling regulates inositol-requiring enzyme 1α activation to protect β-cells against terminal unfolded protein response under irremediable endoplasmic reticulum stress.

Authors:  Tatsuya Ishibashi; Shuhei Morita; Shohei Kishimoto; Shinsuke Uraki; Ken Takeshima; Yasushi Furukawa; Hidefumi Inaba; Hiroyuki Ariyasu; Hiroshi Iwakura; Hiroto Furuta; Masahiro Nishi; Feroz R Papa; Takashi Akamizu
Journal:  J Diabetes Investig       Date:  2020-02-17       Impact factor: 4.232

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.